Dr. Lee-may Chen, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 146
Licensed in California since 1996, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
CA license G83192 (first issued 1996; current) -
Obstetrics & Gynecology Physician
CA license G83192 (first issued 1996; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 146
- Services billed
- 10,421
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 90 | 53 |
| Established patient office or other outpatient visit, 20-29 minutes | 71 | 64 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 56 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 44 | 24 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in San Francisco, CA | 20 |
| Dexamethasone Other prescribers in San Francisco, CA | 16 |
| Prochlorperazine Maleate Other prescribers in San Francisco, CA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 7 payments worth $265 in total to this clinician.
| Taiho Oncology, Inc. | $136 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $88.63 |
| Caris Mpi, Inc. | $39.44 |
| Speaking at a medical education program | $167 |
|---|---|
| Travel and Lodging | $57.54 |
| Food and Beverage | $40.35 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Taiho Oncology, Inc. Mar 29, 2025 | Speaking at a medical education program | $99.19 |
| AstraZeneca Pharmaceuticals LP Mar 29, 2025 | Speaking at a medical education program | $67.45 |
| Taiho Oncology, Inc. May 31, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $31.15 |
| AstraZeneca Pharmaceuticals LP May 31, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $21.18 |
| Taiho Oncology, Inc. Apr 30, 2025 | Travel and Lodging travel to Orlando, FL | $5.21 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $11,820 in research payments for these studies, mostly to the institutions running them.
- A phase 3, randomized, double-blind, placebo-controlled, multicenter s
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.